UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) January 29, 2013

 

HUBEI MINKANG PHARMACEUTICAL LTD.
(Exact name of registrant as specified in its charter)

 

Nevada
(State or other jurisdiction
of incorporation

000-53231
(Commission
File Number)

26-2410685
(IRS Employer
Identification No.)


55 Ubi Ave. 3, #03-01, Mintwell Building
Singapore
(Address of principal executive offices)

408864
(Zip Code)

Registrant's telephone number, including area code +65-6747-7883

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]     Written communications pursuant to Rule 425 under the Securities Act
        (17 CFR 230.425)
[ ]    Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)
[ ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
      (17 CFR 240.14d-2(b))
[ ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
     (17 CRF 240.13e-4(c))


SECTION 3 - SECURITIES AND TRADING MARKETS

Item 3.02 Unregistered Sales of Equity Securities

On January 29, 2013, we completed a private placement financing involving the sale of 8,011,606 restricted shares of our common stock (each a "Share") to fourteen individuals and one entity at a subscription price of $0.20 per Share for gross proceeds of $1,602,321.20.

In connection with the issuance of the Shares, we relied on the exemption from registration under the United States Securities Act of 1933, as amended, provided by Regulation S, based on representations and warranties provided by the purchasers of the Shares in the subscription agreements entered into between the purchasers and us.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: January 31, 2013

Hubei Minkang Pharmaceutical Ltd.

By:

 

/s/ Lee Tong Tai

Name:

 

Lee Tong Tai

Title:

 

President and Director